Clinical trial
Sorafenib in Treating Patients With Metastatic Breast Cancer
NCT00096434 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00096434 |
|---|---|
| Title | Sorafenib in Treating Patients With Metastatic Breast Cancer |
| Official title | Phase II Trial of Raf Kinase Inhibitor BAY 43-9006 as Single Oral Agent in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Drug, Other |
| Interventions | sorafenib tosylate, laboratory biomarker analysis |
| Enrollment | 23 |
| Start date | Sep 1, 2004 |
| Primary completion | Jun 1, 2006 |
| First posted | Nov 10, 2004 |
| Last update posted | Mar 7, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: